The endothelial cell layer is a cell monolayer on the surface of the vascular lumen. It separates circulating blood from the vascular wall and releases active substances to maintain vascular structures and functions. The endothelial cell is an active endocrine and paracrine organ. It releases biologically active substances under both physiological and pathological conditions.
Nitric oxide (NO) generated by endothelial nitric oxide synthetase (eNOS) is the most important factor released by endothelial cells. Most physiological effects of NO in cells occur via activation of guanylyl cyclase-coupled receptors in vascular smooth muscle cells. This process results in cyclic 3′-5′ guanosine monophosphate accumulation and vascular smooth muscle cell relaxation (ie, endothelium-dependent relaxation). Thus, endothelial function is defined by NO bioactivity modulated by the production of NO from eNOS and/or the inactivation of NO by reactive oxygen species (ROS) such as superoxide anions . The endothelial cell is also the main site for generation; the reaction of NO with at a diffusion-controlled rate inactivates NO and forms peroxynitrite (ONOO-). Peroxynitrite is a potent oxidant, and study results indicate that generation and the consequent production of ONOO- causes endothelial dysfunction in cardiovascular diseases (CVDs) including hypertension, atherosclerosis, and coronary heart disease.
Diabetes is a disorder characterized by the elevation of blood sugar. The most common and devastating complications of diabetes occur in the cardiovascular system. Adults with diabetes have a two- to three-fold increased risk of heart attacks and strokes. Endothelial dysfunction is one of the earliest detectable pathological events during the early-onset period of diabetes in humans. Clinical trials with large sample sizes found that the hyperglycemia characteristic of diabetes is the most important causative factor for endothelial dysfunction and accelerated CVD in individuals with diabetes. The landmark Diabetes Control and Complications Trial found that intensive control of blood glucose effectively reduces the risk of development of complications in individuals with type 1 diabetes. These benefits remain despite less intensive blood sugar control by many patients years after the Diabetes Control and Complications Trial study ended.
Adenosine monophosphate-activated protein kinase (AMPK) is a three-subunit (α, β, γ) enzyme ubiquitously distributed throughout the mammalian cardiovascular system, including endothelial cells.[9–12] AMPK is a sensor of cellular energy status (energy sensor) and a major regulator of energy metabolism.[9–12] We and others found that AMPK has a broad range of functions in the cardiovascular system. Our research group was the first to report that AMPK is activated by low levels of free radicals and oxidants (redox sensor); in return, oxidant-mediated AMPK activation effectively suppresses oxidant production (redox modulator). Metformin, a potent AMPK activator, activates AMPK in a redox-sensitive manner. AMPK activation effectively prevents endothelial dysfunction and atherosclerosis-related CVD in mice and human patients. In this mini-review, we will summarize the roles and etiology of endothelial dysfunction in diabetes. We will then present evidence to support the hypothesis that AMPK is a redox sensor and modulator, and AMPK dysfunction plays a crucial role in the initiation and progression of endothelial dysfunction in patients with diabetes.
Etiology of endothelial dysfunction in diabetes
Cardiovascular complications in patients with diabetes are the most common and devastating manifestations of the disease and are the major cause of hospital admissions.[15,16] Accelerated atherosclerosis is one striking feature of these complications and is associated with metabolic syndrome, insulin resistance, and oxidative stress.[17–23] Endothelial cells have crucial roles in the maintenance of cardiovascular homeostasis. They are a physical barrier between the lumen and vessel wall and secrete molecules that regulate coagulation, platelet aggregation, vascular tone, and fibrinolysis. Endothelial dysfunction is characterized by reduced bioavailability of vasodilators (mainly NO) and/or increased numbers and concentrations of endothelium-derived contracting factors. This imbalance impairs endothelium-dependent vasodilation and the impairment manifests as the functional characteristics of endothelial dysfunction. Endothelial dysfunction also includes endothelial activation, which is characterized by a proliferative, proinflammatory, and procoagulatory state that supports the entire progression of atherogenesis.[26,27] Endothelial dysfunction occurs early ahead of structural vessel wall changes detected using angiography or ultrasound. Endothelial dysfunction is a consistent finding in patients with diabetes; it manifests as impairment of NO production and activity, and endothelial dysfunction is a driving force during the development and progression of cardiovascular complications in diabetes. Indeed, targeting endothelial injury may be an effective approach for the management of diabetes-associated vascular disorders and therapeutic interventions aimed at improving endothelial function in patients with diabetes have been tested in clinical trials.
Diabetes Control and Complications Trial and United Kingdom Prospective Diabetes Study findings revealed the efficacy of intensive glucose control for reducing the risk of diabetes-associated microvascular complications (eg, retinopathy, neuropathy, and nephropathy).[30,31] Findings of Diabetes Control and Complications Trial from long-term follow-up of participants found a decreased incidence in atherosclerosis in those with intensively-controlled blood glucose concentrations. This result suggests that hyperglycemia is important in the development of macrovascular diseases in patients with diabetes. There is an abnormality in endothelium-dependent relaxation in individuals in whom blood glucose and insulin levels are acutely increased using glucose infusion.[8,32] Multiple pathways can be involved with the dysfunction and activation of endothelial cells induced by hyperglycemia, including enhanced glycolysis, the formation of glycolysis intermediates, and advanced glycation end (AGE) product modifications.
Free fatty acids
Hyperglycemia is just one of many metabolic abnormalities associated with diabetes. Another contributing factor for endothelial dysfunction in diabetes is the elevation of circulating free fatty acids (FFAs).[32–34] Impaired glucose tolerance can occur in young normoglycemic relatives of patients with high FFAs.[8,32–34] An increase in FFAs is an important feature of diabetes and is common in type 1 and type 2 forms of the disease.[17,35] High levels of plasma FFAs caused by infusing a lipid emulsion and heparin impairs endothelium-mediated vasodilatation (and NO production) in human volunteers undergoing the hyperinsulinemic-euglycemic clamp technique.[36,37] Patients with obesity and type 2 diabetes have elevated plasma FFA levels, which play detrimental roles in the etiology of atherosclerosis and CVD. FFA-driven endothelial dysfunction occurs through mechanisms including impairment of insulin signaling and reduction of NO, inflammation, oxidative stress, endothelial cell apoptosis, and activation of the renin-angiotensin system. Targeting signaling pathways involving FFA-induced endothelial dysfunction can be used to prevent endothelial dysfunction and subsequent complications, such as atherosclerosis.
Insulin resistance plays a pathophysiological role in type 2 diabetes.[39,40] Insulin regulates glucose homeostasis by promoting glucose disposal in skeletal muscle and adipose tissue, inhibiting gluconeogenesis in the liver, and regulating the transport of nutrients to target tissues via actions on the microvasculature. Insulin-induced NO production from the vascular endothelium leads to increased blood flow that further enhances glucose uptake in skeletal muscle. Insulin resistance is frequently associated with endothelial dysfunction and has been proposed to have a major role in CVD. The balance between the NO-dependent vasodilator actions and endothelin-1-dependent vasoconstrictor actions of insulin is regulated by phosphatidylinositol 3-kinase-dependent and mitogen-activated protein kinase-dependent signaling in vascular endothelium. During insulin-resistant conditions, phosphatidylinositol 3-kinase-dependent signaling impairment can cause an imbalance between the production of NO and the secretion of endothelin-1 and lead to endothelial dysfunction.
Metabolic conditions, such as obesity and type 2 diabetes mellitus (insulin resistance) are associated with inflammation. Adipocytes can constitutively express tumor necrosis factor alpha (TNF-α). Expression of this important proinflammatory cytokine is markedly increased in animal models of obesity. Using soluble TNF-α receptors to neutralize TNF-α receptors can reduce insulin resistance in these animal models. These findings first linked the increased expression of a proinflammatory cytokine to insulin resistance. The results of studies in humans support these findings. Diabetes and obesity (the main risk factor for type 2 diabetes) are inflammatory diseases, as indicated by elevated plasma concentrations of interleukin 6 (IL-6), C-reactive protein, and plasminogen activator inhibitor 1.[13,44,45] Experimental and clinical investigations found that vascular inflammation has an important role in the progression of endothelial dysfunction. In endothelial dysfunction, the endothelium loses its physiological properties, reduces the bioavailability of NO, and changes to a state of vasoconstriction, thrombosis, and inflammation. Inflammation is essential for the development of vascular complications in individuals with obesity and type 2 diabetes. Anti-inflammatory adiponectin can protect endothelial function, and interventions to reduce inflammation (eg, administration of salicylate) can prevent vascular dysfunction and cardiovascular events.
Oxidative stress and diabetes-associated endothelial dysfunction
Hyperglycemia is the fundamental abnormality in diabetes and is associated with oxidative stress. Hyperglycemia perpetuates oxidative stress by releasing from multiple sources from endothelial cells [Figure 1]. Although has been previously recognized as an important cytotoxic factor contributing to tissue damage, alone does not exhibit high reactivity towards most types of biological molecules. can be highly reactive after its reaction of NO to yield a potent oxidizing species ONOO- by a direct bimolecular reaction of NO with at near diffusion-limited rates (6.7 × 109.mol−1.s−1) [Figure 1]. This rate constant of NO with is 3 times faster than the enzymatic dismutation of catalyzed by superoxide dismutase (SOD) at neutral pH (Ksod = 2 × 109.mol−1.s−1). Thus, depending upon local rates of production of both NO and , ONOO- formation represents a major potential pathway of NO reactivity.
Overwhelming evidence supports a causative role of oxidative stress in the development and progression of endothelial dysfunction in diabetes. In patients with diabetes, increased plasma levels of ROS markers like thiobarbituric acid-reactive substances, 8 alpha-isoprostanes, oxidized low-density lipoprotein (oxLDL), protein oxidation products, 8-oxo-deoxyguanosine, and 8-oxoguanosine have been found along with decreased antioxidant defenses (eg, total antioxidant capacity, bilirubin, SOD, and antioxidant vitamins). The sources of oxidative stress in diabetes include non-enzymatic, enzymatic, and mitochondrial pathways. The non-enzymatic mechanisms include generation of hydroxy (OH) via auto-oxidation of glucose and formation of AGEs. Enhanced metabolism of glucose via the polyol pathway produces ; stimulation of the renin-angiotensin system in diabetes also promotes ROS formation. The enzymatic sources of ROS generation in diabetes include NOS, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX), and xanthine oxidase. Xanthine oxidase mediates the final 2 reactions of the purine metabolism pathway and generates significant amounts of ROS. The and other ROS produced can then stimulate signaling pathways associated with cell growth and the inflammation, apoptosis, and fibrosis that eventually lead to the development of the complications of diabetes.[55,56]
With respect to oxygen-derived free radicals and oxidants, study results indicate that oxidative stress has a vital role in the pathogenesis of complications associated with diabetes.[57,58] Hyperglycemia-induced oxidative stress may be the earliest event associated with progression of inflammation. Although insulin resistance has been attributed to the inflammatory processes starting in adipose tissue, study results suggest that endothelial dysfunction represents the upstream event that precedes peripheral impairment of insulin sensitivity. Suppression of ROS-dependent pathways in the endothelium restores insulin delivery to peripheral organs by preserving NO availability. Such a disruptive effect of ROS in diabetes is supported by the comparable endothelial dysfunction in vitamin E-deprived rats.[61,62] Similarly, defective endothelium-dependent vasodilation in subjects with type 2 diabetes[33,63,64] can be reversed using dietary ascorbic acid. This effect of ascorbic acid also occurs in patients with type 1 diabetes.[66,67] As detailed below, several enzymatic systems in diabetic endothelial cells are activated to become a main source of .
PNOX is a membrane-associated, heme-containing enzyme complex consisting of 7 subunits and is a major source of production in diabetes. Vascular NOX consists of multiple subunits, including p22phox, p40phox, p47phox, p67phox, Nox organizer 1 (NoxO1), Nox activator 1 (NoxA1), Rac1, and unique NOX isoforms (based on gp91phox). NOX isoforms are catalytic subunits for ROS generation. They are differentially expressed and regulated in various cell types and pathological conditions but remain to be fully characterized. Seven homologues of the NOX family have been identified: Nox1-5, DUOX1, and DUOX2. Endothelial cells and endothelial progenitor cells predominantly express Nox2, Nox4, and Nox1 isoforms.
Activation of NOX is implicated in oxidative stress associated with hyperglycemia. Protein kinase C beta-dependent NOX activation has been suggested as the major source of oxidants in diabetes. Treatment of human umbilical vein endothelial cells with high glucose increases NOX expression, apoptosis, and levels of oxidative stress markers. ROS production and expression of p22phox increase in mouse microvascular endothelial cells treated with high glucose. A human clinical study found that NOX expression and activity was augmented in the metabolic syndrome group compared with the cardiovascular risk factor and control groups. Oxidized LDL and 3-nitrotyrosine levels and carotid intima-media thickness increased in the metabolic syndrome group compared with the cardiovascular risk factor and control groups; these changes were related to the NOX oxidase activity in the overall population. These findings suggest that abnormal activation of NOX is involved in oxidative stress and atherosclerosis in patients with metabolic syndrome.
NOX-dependent superoxide production links palmitate-stimulated toll-like receptor 4 activations to nuclear factor-κB (NF-κB) signaling in endothelial cells. FFA-induced NOX subunit overexpression and ROS production could be involved in the endothelial dysfunction in obese Zucker diabetic fatty rats. Study results suggest that pitavastatin or NOX inhibitors protect against the effects of these changes. Higher levels of superoxide in insulin-resistant endothelial cells can be pharmacologically inhibited (both acutely and chronically) using the NOX inhibitor, gp91ds-tat. Similarly, insulin resistance-induced impairment of endothelial-mediated vasorelaxation can be reversed using gp91ds-tat. Knockdown of Nox2, which is specifically elevated in insulin-resistant endothelial cells, can significantly reduce superoxide levels. Double transgenic mice with endothelial-specific insulin resistance and deletion of Nox2 have reduced superoxide production and improved vascular function. This study identified Nox2 as the central molecule in insulin resistance-mediated oxidative stress and vascular dysfunction. It also established pharmacological inhibition of Nox2 as a novel therapeutic target in insulin resistance-related vascular disease.
Electron transport chain
The electron transport chain can generate ROS under physiological and pathological conditions. In diabetes, persistent hyperglycemia elevates FFA levels. FFAs are metabolized to produce increased levels of reduced coenzymes (nicotinamide adenine dinucleotide and flavin adenine dinucleotide). These reduced coenzymes enter the respiratory chain, and consequently, increase the production of to combat the flux of electrons. In diabetes, this mitochondrial stimulates the production of more ROS and reactive nitrogen species via activation of NF-κB-mediated cytokines, protein kinase C, and NOX.[53,56]
In diabetes, excessive mitochondrial ROS production has been implicated as a “master switch” for activation of discrete pathologic signaling pathways leading to subsequent endothelial dysfunction through protein kinase C activation, increased AGE formation, and increased polyol and hexosamine pathway flux.In vivo, human studies found that hyperglycemia induces this endothelial dysfunction via excessive oxidative stress. The relationship between human endothelial dysfunction and alterations in endothelial and inflammatory cell mitochondrial homeostasis in diabetes is relatively unstudied. Some study findings suggest that altered mitochondrial homeostasis has an important pathophysiologic role in endothelial dysfunction in diabetes.[78,79]
There is growing recognition of a link between mitochondrial morphology and function. This link is apparent in diabetes and insulin resistance. These conditions are characterized by alterations in mitochondrial morphology, including smaller mitochondria with a less complicated structure and reduced capacity for oxidative phosphorylation, elevated mitochondrial membrane potential, and reduced mitochondrial mass.[81,82] Microarray analyses of skeletal muscle from patients with diabetes reveal reduced expression of components of the oxidative phosphorylation pathway. This change can be reversed by peroxisome proliferator-activated receptor gamma coactivator 1 alpha, which has an integral role in the regulation of mitochondrial biogenesis.In vitro cell culture and muscle biopsy results indicate decreased mitochondrial mass under hyperglycemic conditions, and this derangement is also present in offspring of patients with insulin-resistant type 2 diabetes.[79,81]
In endothelial cells, hyperglycemia induces mitochondrial fission with subsequent development of excessive mitochondrial ROS production, reduced adenosine triphosphate production, and blunted cell growth. Results from endothelial cell-culture indicate that exposure to high glucose concentrations increases endothelial ROS production. This phenomenon is primarily related to the increased mitochondrial ROS because blunting of the effect occurs only with pharmacologic inhibition of complex II, overexpression of mitochondrial uncoupling protein 1, or exposure to manganese SOD. Indicative of the cell-signaling capacity of mitochondrial ROS, mitochondrial ROS inhibitors also reduce NF-κB and protein kinase C activation and reduce the production of toxic AGE products and sorbitol. Expression of cell-adhesion molecules on the endothelial cell surface depends on mitochondrial ROS when high glucose concentrations are present.[79,84,85] Exposure of endothelial cells to high concentrations of FFAs increases mitochondrial membrane potential, mitochondrial ROS, and NF-κB in human aortic endothelial cells. Each of these responses is inhibited by overexpression of uncoupling protein 2 (UCP2). Therefore, reductions in mitochondrial ROS, together with the reductions in mitochondrial membrane potential, are responsible for the observed improvement in endothelial function. Similarly, in intact vessels, overexpression of UCP2 in the rat aorta reverses endothelial dysfunction induced by lysophosphatidylcholine.[32,86]
Mitochondrial fission could be an effective target to improve diabetic endothelial function. Metformin reduces diabetes-accelerated development of atherosclerosis by inhibiting mitochondrial fission in endothelial cells. Metformin treatment significantly reduces streptozotocin-induced mitochondrial fragmentation, suppresses mitochondrial superoxide production, inhibits vascular inflammation, improves endothelium-dependent vasodilation, and inhibits atherosclerotic lesions in diabetic apolipoprotein E knockout (ApoE-/-) mice. In endothelial cells exposed to high glucose concentrations, metformin treatment suppresses mitochondrial superoxide production, reduces levels of dynamin-related protein 1 (DRP1) and its transport to mitochondria, and prevents mitochondrial fission.
Mitophagy is an important cytoprotective mechanism for limiting mitochondrial-derived oxidative stress and preventing apoptosis. However, excessive fission occurs under pathological conditions, especially in diabetes mellitus. This change negatively affects mitophagy and results in increased levels of mitochondrial fragmentation, ROS overproduction, and accumulation of dysfunctional mitochondria. The increased ROS further accelerates mitochondrial oxidative damage and cytochrome C release to the cytosol, which amplifies apoptosis. Thus, targeting improvement in mitophagy may be a promising method of treatment for endothelial oxidative damage in diabetes.
Defense mechanisms in the form of antioxidants are present in the body to counteract oxidative stress. They include enzymes like SOD, catalase, glutathione peroxidase, and the fat- (bilirubin, coenzyme Q, vitamin A, and vitamin E) and water-soluble (vitamin C and uric acid) antioxidants. A general reduction in antioxidant defense mechanisms occurs in diabetes.[51,53,56] Low levels of serum carotenoid also play a role in the development of insulin resistance and diabetes. Antioxidant therapy achieved using supplementation with pharmaceutical preparations of antioxidant nutrients or non-nutrients,[93,94] or both, may confer cardiovascular and metabolic benefits in diabetes. Experimental findings indicate that antioxidants improve endothelium-dependent vasodilation and insulin sensitivity. Results of epidemiological studies indicate there are strong associations between dietary intake of antioxidant nutrients and protection against CVD.[95–97]
Hyperglycemia inhibits endothelial function in the forearm microvasculature via suppression of NO bioavailability. This reduced dilation during acute hyperglycemia is also found in patients with diabetes and can be improved using antioxidant therapy.[65,66,98] NO has important antioxidant activities in the vessel wall, including direct scavenging of superoxide anions and inhibition of lipid peroxidation.[99–101] The efficiency of NO in its antioxidant role can make basal endothelium-dependent, NO-mediated vasodilator function especially vulnerable to inhibition during an oxidative insult. Conversely, loss of basal endothelium-derived NO in this manner can also help preserve vasodilator responses to endothelial agonists and NO donors. However, any lesion in the endogenous NO signaling pathway has major pathological implications for microangiographic disease progression in diabetes. Dysregulation of vascular tone, the proliferation of vascular smooth muscle cells, platelet aggregation, coagulation, fibrinolysis, leukocyte adhesion, vascular permeability, and lipoprotein oxidation contribute to the progression of the disease. Many of these pro-atherogenic sequelae can be triggered by hyperglycemia via formation of AGE, which inactivates NO to generate endothelial intracellular oxidant stress.[79,98,102,103]
Study results suggest that diminution of endothelial synthesis of NO contributes to the pathogenesis of type 2 diabetes. In addition to detracting from the vascular antioxidant defense, this change compounds any defect in the anti-atherogenic signaling role of NO.[67,104] The 3 isoforms of NOS (eNOS, neuronal NOS, and inducible NOS) require 5 cofactors/prosthetic groups (flavin adenine dinucleotide, flavin mononucleotide, heme, 5,6,7,8-tetrahydrobiopterin, and Ca-calmodulin) to convert l-arginine to NO. If NOS lacks any of the cofactors or substrates, it will switch from the coupled state of NO production to the uncoupled state of production. The resulting reacts with the preformed NO to form ONOO-, which is an extremely potent oxidizing agent. Peroxynitrite, in turn, can oxidize the cofactor of eNOS and 5,6,7,8-tetrahydrobiopterin to 7,8-tetrahydrobiopterin, thus further uncouple NO generation. The increased pro-oxidant activity can facilitate oxidation of LDL to oxLDL particles, which can limit the availability of l-arginine, enhance the uncoupling of NOS, and contribute to increased ROS generation and decreased availability of NO in diabetes.[54,56] ONOO--mediated tyrosine nitration of prostacyclin synthase contributes to vascular complications in diabetes mellitus. In diabetes, hyperglycemia or hyperlipidemia increases and ONOO- generation, which results in prostacyclin synthase nitration and subsequent thromboxane receptor stimulation. ONOO- also promotes endothelium-derived cyclooxygenase-dependent vasoconstriction factor release via accumulation of non-metabolized prostaglandin H2. Thus, ONOO--dependent prostacyclin synthase nitration shifts the balance toward platelet aggregation, atheroma, and thrombus formation.
Results of studies performed by us[105,106] and others suggest that 3 correlated mechanisms are involved in the regulation of eNOS uncoupling via and then ONOO- in diabetes. They include (1) oxidative modification of tetrahydrobiopterin (BH4) into dihydrobiopterin; (2) regulation of the zinc-thiolate center of eNOS, leading to zinc-depleted eNOS dimers and reduction of affinity to BH4 and l-arginine; and (3) ubiquitination and proteasomal degradation of guanosine triphosphate cyclohydrolase 1, a rate-limiting enzyme in BH4 synthesis. We found that generated from hyperglycemia can quench NO to form ONOO-, a powerful oxidant that not only causes prostacyclin synthase nitration and thromboxane receptor activation but also uncouples eNOS to produce oxidants.[105,108]
Adenosine monophosphate-activated protein kinase and diabetic endothelial dysfunction
The heterotrimer AMPK comprises α, β, and γ subunits. Each subunit has at least 2 isoforms.[9–12] The α subunit contains the catalytic site. Increases in the Adenosine monophosphate (AMP)/adenosine triphosphate (ATP) ratio activate AMPK via mechanisms including direct allosteric activation and phosphorylation of the α subunit at Thr-172 by an AMP-dependent AMPK kinase (AMPKK). Until 2013, AMPKK was thought to be activated by an increase in the AMP/ATP ratio. However, study results indicate that AMP binding to AMPK makes it more susceptible to phosphorylation by AMPKK.[110–112] Liver kinase B1 (LKB1) was the first AMPKK identified.[110–113] A gene mutation in this tumor suppressor increases the risk of colon, stomach, and pancreatic cancer (Peutz-Jegher syndrome). Calcium calmodulin-dependent kinase was the second AMPKK identified.[114,115]
AMPK is activated in response to stresses such as hypoxia, oxidant stress, hyperosmolarity, and exercise (in muscle). Other studies indicate that AMPK activation is a fundamental component of cellular responses to stress that threaten viability.[116–118] AMPK can be phosphorylated and activated in various tissues by hormones acting through Gq receptors, adiponectin,[116,117] leptin,[118,119] α and β-adrenoreceptor agonists, metformin,[121–123] the thiazolidinediones, and oxidants such as ONOO- and hydrogen peroxide. AMPK activation results in phosphorylation of target molecules to increase fatty acid oxidation and muscle glucose transportation; it also inhibits synthetic processes to conserve ATP. Acetyl CoA carboxylase (ACC) and 3-hydroxy-3-methyl-glutaryl CoA reductase were the first identified AMPK targets. Other AMPK targets are being identified at a rapid rate. AMPK inhibits proliferation through multiple mechanisms. These mechanisms include cell cycle regulation, inhibition of protein synthesis, and de novo synthesis of fatty acids, particularly mevalonate and its downstream products during cholesterol synthesis. Dual deficiency of AMPK α1 and α2, 2 catalytic subunits of AMPK, is lethal to mouse embryos, which indicates the importance of AMPK.
AMPK in endothelial cells
Compared with AMPKα2, AMPKα1 is predominantly expressed in endothelial cells. However, both isoforms might have equal roles in the maintenance of endothelial function. In endothelial cells, the activity of AMPK can be regulated by stimuli that affect cellular ATP levels (eg, hypoxia) and by fluid shear stress, Ca2+-elevating agonists, and hormones such as adiponectin. The AMPK in endothelial cells is implicated in the regulation of fatty acid oxidation, small G protein activity, NO production, inflammation, and angiogenesis. AMPKα1[125,130,131] and α2 increase NO release by phosphorylating both Ser1177 and Ser635 of eNOS in endothelial cells. Selective deletion of endothelial PRKAA1 coding for protein kinase AMPKα1 reduces glycolysis, compromises endothelial cell proliferation, and accelerates the formation of atherosclerotic lesions in hyperlipidemic mice. Endothelial-specific deletion of the AMPKα1 subunit attenuates phenylephrine-mediated contraction in an eNOS- and endothelium-dependent manner. AMPKα2-/- mice have impairment of acetylcholine-induced endothelium-dependent relaxation, along with increased oxidant production.
AMPK activation suppresses oxidative stress
AMPK is dysregulated in animals and humans with type 2 diabetes or metabolic syndrome. AMPK activation via physiological or pharmacological means can improve the sensitivity of insulin and metabolic hemostasis. Various hormones, natural compounds, and pharmacological agents can activate AMPK. Some, like metformin and thiazolidinediones, are used to treat type 2 diabetes. Metformin is also used off-label to limit the insulin dose requirement during treatment of type 1 diabetes. Results of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial indicate that metformin treatment in type 1 diabetes can alleviate atherosclerosis progression and reduce LDL-cholesterol levels and body weight. These findings suggest a new perspective on the therapeutic activation of AMPK in type 1 diabetes and indicate a potential role in the reduction of long-term CVD risk. For instance, chicoric acid is likely to protect against diabetes-induced endothelial dysfunction via the activation of the AMPK signaling pathway. AMPK is an important candidate for the effective treatment of the diabetes-associated vascular endothelial injury.
AMPK and NOX
Hyperglycemia is the core determinant of long-term complications in diabetes, mainly via induction of oxidative stress. Ido et al found that incubation with the first direct AMPK activator, 5-aminoimidazole-4-carboxamide riboside (AICAR), completely prevents hyperglycemia-drive oxidative stress and apoptosis. This result suggests that AMPK has a protective role against damage in endothelial cells resulting from sustained hyperglycemia. NOX is the major source of high glucose-induced oxidative stress. Study results indicate that AMPK activation functions as a NOX inhibitory mechanism via regulation of NOX complex assembly or NOX subunit expression. For instance, AMPK inhibits activation of NOX in human neutrophils. Treatment of neutrophils with AICAR or AMP suppresses the rise in production triggered by phorbol esters or N-formylmethionyl-leucyl-phenylalanine. AMPK activity prevents the serine phosphorylation and membrane translocation of p47phox induced by these agonists. A widely used antidiabetic drug, metformin, inhibits production by stimulated neutrophils, and in platelets. Genetic deletion of AMPKα2 in LDL receptor-knockout LDLr-/- mice significantly increases 26S proteasome activity, I-κB degradation, NF-κB transactivation, NOX subunit expression, ROS production, and endothelial dysfunction. All these effects are markedly suppressed by long administration of the proteasome inhibitor, MG132. These findings suggest that AMPKα2 is a physiological inhibitor of NOX in endothelial cells. As a result, AMPK is essential in maintaining the non-atherogenic and non-inflammatory conditions in endothelial cells. Rosiglitazone activates AMPK in endothelial cells which, in turn, prevents hyperactivity of NOX induced by high glucose, possibly through protein kinase C inhibition. Taken together, these results suggest that AMPK functions as an “early warning system” in response to oxidant stress and upon activation, AMPK can suppress oxidative injury by suppressing NOX-derived ROS. This feedback mechanism becomes impaired in diabetes, and AMPK inhibition accentuates oxidative stress and vascular injury in diabetes in vivo.
AMPK and the electron transport chain
Mitochondrial ROS levels increase in response to many atherosclerosis-associated stimuli, including hyperglycemia, oxLDL, and triglycerides.[144–146] Pharmacological activation of AMPK by 5-aminoimidazole-4-carboxamide ribonucleotide or salicylate restores mitochondrial morphology and relieves endothelial dysfunction via suppression of mitochondrial ROS, endoplasmic reticulum stress, and subsequent activation of inflammation. AMPK regulates mitochondrial fission via autophagy-dependent degradation of DRP1 in endothelial cells. Deletion of AMPKα1 or AMPKα2 results in defective autophagy, DRP1 accumulation, and aberrant mitochondrial fragmentation in the mouse aortic endothelium. Metformin administration markedly inhibits mitochondrial fragmentation, decreases mitochondrial-induced superoxide, improves endothelium-dependent vasodilation, suppresses vascular inflammation, and alleviates atherosclerotic lesions in streptozotocin-induced diabetic mice. Another study found that metformin attenuates the development of atherosclerosis by reducing DRP1-mediated mitochondrial fission and mitochondrial superoxide anion production in an AMPK-dependent manner. Taken together, these findings suggest that suppression of mitochondrial fission is a potentially effective therapeutic approach for treating macrovascular complications in patients with diabetes. C-peptide prevents diabetic vasculopathy by suppressing ROS-mediated endothelial cell apoptosis. C-peptide activates AMPKα and inhibits high glucose-induced ROS generation, mitochondrial fragmentation, mitochondrial membrane potential decline, and endothelial cell apoptosis. C-peptide replacement therapy restores AMPKα phosphorylation, ROS generation, and mitochondrial morphology in aortas of diabetic mice. These findings reveal a novel mechanism that is associated with the use of C-peptide to activate AMPKα and alleviate hyperglycemia-induced vasculopathy.
Continuously produced ROS can be eliminated by antioxidant systems. AMPK activation can suppress diabetic endothelial dysfunction by upregulating antioxidant potentials. Pharmacological AMPK activator 5-aminoimidazole-4-carboxamide riboside can markedly increase UCP-2 expression and decrease production and prostacyclin synthase nitration in diabetic wild-type mice but not in AMPKα2-KO counterparts. Direct evidence indicates that AMPK activation suppresses hyperglycemia-induced mitochondrial ROS generation via induction of manganese SOD and promotion of mitochondrial biogenesis through the AMPK-peroxisome proliferator-activated receptor gamma coactivator 1 alpha pathway in human umbilical vein endothelial cells.
Taken together, we conclude that AMPK functions as oxidant stress suppressor or redox modulator as its activation can trigger physiological responses to suppress the processes that generate oxidants (mitochondria, NOX) and/or to increase antioxidant defense systems [Figure 2].
Dual effects of oxidative stress on AMPK activity
Reversible and transient activation of AMPK by acute production of low levels of oxidants and ONOO−
A line of evidence supports the responsiveness of AMPK in control of imbalanced redox status.[126,152–154] For instance, the addition of the vitamin E analog and antioxidant, Trolox, to mouse embryonic fibroblasts results in reduced basal AMPK activity. Hydrogen peroxide activates AMPK in various cell types. ROS-triggered energy stress strongly activates AMPK and is likely to be the major mechanism of ROS-caused AMPK activation.[157,158] Alternatively, 1 study found that ROS can directly activate AMPK; this effect is independent of the changes in AMP, adenosine diphosphate, and ATP. Glucose oxidase-generated hydrogen peroxide also contributes to AMPK activation through direct S-glutathionylation on the AMPKα subunit at residues Cys299 and Cys304. Reactive nitrogen species are also implicated in AMPK activation. Subsequent studies from us have further determined that AMPK acts as a proximal “oxidant sensor” within endothelial cells, either through its ability to respond to minimal changes in AMP levels or through its activation by oxidant-initiated signaling events [Figure 3].
Irreversible inhibition of AMPK inhibition by chronic exposure of elevated oxidants such as ONOO−
Study findings support a role for ROS in the impaired endothelium-dependent vasodilation found in various vascular preparations isolated from experimental diabetic animals.[160–165] It is likely that this dysfunction is mainly due to the reduced bioavailability of NO resulting from its rapid inactivation by superoxide radicals.[166,167] This mechanism, together with the production of superoxide anion by “uncoupled” NOS, may generate significant sources of endothelial superoxide anion. AMPK contribution to eNOS bioactivity is supported by in vitro and in vivo work by our group and others. In addition to direct phosphorylation of eNOS to increase NO production, AMPK can promote NO bioactivity by suppressing NO inactivation via reduction of the amount of ROS in the diseased vessel. Non-toxic levels of ROS/ONOO− activate AMPK or AMPK-dependent pathways,[13,125,168–172] while activation of AMPK suppresses ROS/ONOO− generation.
AMPK activity decreases in muscle in multiple animal models with a metabolic syndrome phenotype. Evidence indicates that AMPK activity is diminished in adipose tissue and skeletal muscle of humans with obesity or type 2 diabetes. Decreased AMPK activity and subsequent reduction in cardiac autophagy are important events during the development of diabetic cardiomyopathy. Chronic activation of AMPK by metformin prevents cardiomyopathy by upregulating autophagy activity in diabetic OVE26 mice. This finding suggests that stimulation of AMPK represents a novel approach for treatment of diabetic cardiomyopathy. Hyperglycemia impairs autophagy in human umbilical vein endothelial cells via inhibition of AMPK, which directly results in endothelial cell damage. Diabetes downregulates AMPK and acetyl-CoA carboxylase in mouse aortas. This downregulation can be suppressed by metformin treatment. Similar results are found in cultured human umbilical vein endothelial cells. Endothelial dysfunction caused by a high fat diet is related to a dysfunctional endothelial AMPK-phosphoinositide 3-kinases-protein kinase B-eNOS pathway. The dysfunction correlates with increases in plasma non-esterified fatty acids, triglyceride, and impaired glucose management.
ROS and other reactive molecules can inhibit the LKB-AMPK axis.[179,180] For instance, chemically reactive lipids, such as cyclopentenone prostaglandins (exogenous or generated from cyclooxygenase-2) form a covalent adduct with LKB1 Cys210 in its activation loop and thus inhibit LKB1 kinase activity. Similarly, findings from a study using a spontaneously hypertensive rat model indicate that the development of left ventricular hypertrophy is associated with an increase in the oxidative stress-derived lipid peroxidation byproduct 4-hydroxy-2-nonenal. This increase results in the formation of 4-hydroxy-2-nonenal-LKB1 adducts that inhibit LKB1 and subsequent AMPK activity. However, these two studies did not describe any direct post-translational modification of AMPK by ROS. In conditions of glucose starvation or exogenous hydrogen peroxide treatment, AMPK is negatively regulated by oxidation of cysteine residues Cys130 and Cys174 on its α subunit. The changes cause oxidative aggregation and interfere with the interaction between LKB1 and AMPK.[181,182]
Our unpublished results indicate that in chronic diseases such as diabetes, AMPK becomes a target of excessive oxidative stress. We found that: (1) When given exogenously or when produced in the vasculature from endogenous sources, ONOO- inhibits AMPK activation likely by increasing tyrosine nitration of AMPK. The catalytic activities of AMPKα are exquisitely and uniquely sensitive to pathologically relevant concentrations of ONOO-; (2) Chronic exposure of endothelial cells to elevated glucose concentrations results in loss of AMPK, aberrant overexpression of NOX activity, and increased release similar to that seen with genetic depletion of AMPK. The effects of elevated glucose are prevented by superoxide dismutase-polyethylene glycol or NG-nitro-l-arginine methyl ester (l-NAME); these findings indicate that endogenous generation of ONOO- is responsible for the AMPK loss; (3) Direct demonstration of the occurrence of AMPK nitration in endothelial cells exposed to hyperglycemia and in tissues from diabetic mice. Overall, our results support the hypothesis that AMPK is inhibited by pathologically relevant concentrations of ONOO- generated in a diabetic milieu.
Endothelial dysfunction is the earliest detectable pathological event in diabetes. Glucose levels elevated via the increased production of free radicals and oxidants are likely to be the main causes of endothelial dysfunction. Our work has firmly established that AMPK in endothelial cells is activated by very low levels of free radicals and oxidants; activation of AMPK by low levels of oxidants can feedback to the suppression of oxidant stress, either via its suppression on multiple sources (NOX, mitochondria, etc) and/or the promotion of antioxidant enzyme levels within endothelial cells. As a result, AMPK reverses or prevents endothelial dysfunction caused by diabetes, and aberrant oxidant stress-induced AMPK inactivation accelerates both endothelial dysfunction and CVD in diabetes. Based on these observations, we propose that besides the traditional ATP/ADP/AMPK regulation pathway and traditional roles of AMPK in energy metabolism, AMPK is the main sensor in redox homeostasis and is critical for maintaining redox homeostasis by suppressing the levels of oxidant stress [Figure 4].
In summary, we conclude that AMPK inactivation caused by aberrant oxidant stress plays a crucial role in endothelial dysfunction in diabetes. Selective AMPK activation can effectively treat endothelial dysfunction in diabetes by normalizing the critical roles of AMPK for maintenance of endothelial cell redox homeostasis.
The authors sincerely thank Dr. Ming-Hui Zou's current and former members for their great contributions to the works cited in this review.
The work described in this review was supported by NIH grants to Dr. Ming-Hui Zou (NHLBI (HL079584, HL080499, HL089920, HL110488, HL128014, HL132500, HL137371, and HL142287), NCI (CA213022), NIA (AG047776)).
Conflicts of interest
. Tousoulis D, Kampoli AM, Tentolouris C, et al. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 2012;10(1):4–18. doi: 10.2174/157016112798829760.
. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989;3(9):2007–2018.
. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996;271(5 Pt 1):C1424–C1437. doi: 10.1152/ajpcell.1996.271.5.C1424.
. Higashi Y, Maruhashi T, Noma K, et al. Oxidative stress
and endothelial dysfunction: clinical evidence and therapeutic implications. Trends Cardiovasc Med 2014;24(4):165–169. doi: 10.1016/j.tcm.2013.12.001.
. Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 2015;6(13):1246–1258. doi: 10.4239/wjd.v6.i13.1246.
. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001;22(1):36–52. doi: 10.1210/edrv.22.1.0417.
. Funk SD, Yurdagul A Jr, Orr AW. Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. Int J Vasc Med 2012;2012:569654. doi: 10.1155/2012/569654.
. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348(23):2294–2303. doi: 10.1056/NEJMoa022314.
. Hardie DG, Carling D. The AMP-activated protein kinase – fuel gauge of the mammalian cell. Eur J Biochem 1997;246(2):259–273. doi: 10.1111/j.1432-1033.1997.00259.x.
. Hardie DG, Carling D, Halford N. Roles of the Snf1/Rkin1/AMP-activated protein kinase family in the response to environmental and nutritional stress. Semin Cell Biol 1994;5(6):409–416. doi: 10.1006/scel.1994.1048.
. Kemp BE, Mitchelhill KI, Stapleton D, et al. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 1999;24(1):22–25. doi: 10.1016/s0968-0004(98)01340-1.
. Mitchelhill KI, Stapleton D, Gao G, et al. Mammalian AMP-activated protein kinase shares structural and functional homology with the catalytic domain of yeast Snf1 protein kinase. J Biol Chem 1994;269(4):2361–2364.
. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 2009;120(13):1266–1286. doi: 10.1161/CIRCULATIONAHA.108.835223.
. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577–1589. doi: 10.1056/NEJMoa0806470.
. Wild S, Macleod F, McKnight J, et al. Impact of deprivation on cardiovascular risk factors in people with diabetes: an observational study. Diabet Med 2008;25(2):194–199. doi: 10.1111/j.1464-5491.2008.02382.x.
. Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA 2004;292(20):2495–2499. doi: 10.1001/jama.292.20.2495.
. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37(12):1595–1607. doi: 10.2337/diab.37.12.1595.
. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities--–the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334(6):374–381. doi: 10.1056/NEJM199602083340607.
. Jacob S, Machann J, Rett K, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999;48(5):1113–1119. doi: 10.2337/diabetes.48.5.1113.
. Paolisso G, Giugliano D. Oxidative stress
and insulin action: is there a relationship. Diabetologia 1996;39(3):357–363. doi: 10.1007/BF00418354.
. Jiang ZY, Lin YW, Clemont A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999;104(4):447–457. doi: 10.1172/JCI5971.
. Ido Y, Carling D, Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 2002;51(1):159–167. doi: 10.2337/diabetes.51.1.159.
. Bohlen HG, Nase GP. Arteriolar nitric oxide concentration is decreased during hyperglycemia-induced betaII PKC activation. Am J Physiol Heart Circ Physiol 2001;280(2):H621–627. doi: 10.1152/ajpheart.2001.280.2.H621.
. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. Br J Pharmacol 2000;130(5):963–974. doi: 10.1038/sj.bjp.0703393.
. Lerman A, Burnett JC Jr. Intact and altered endothelium in regulation of vasomotion. Circulation 1992;86(6 Suppl):III12–III19. doi: 10.1161/01.CIR.0000131515.03336.f8.
. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999;34(3):631–638. doi: 10.1016/s0735-1097(99)00259-4.
. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23(2):168–175. doi: 10.1161/01.atv.0000051384.43104.fc.
. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109(23 Suppl 1):III27–III32. doi: 10.1161/01.CIR.0000131515.03336.f8.
. Avogaro A, Albiero M, Menegazzo L, et al. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 2011;34(Suppl 2):S285–S290. doi: 10.2337/dc11-s239.
. Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977–986. doi: 10.1056/NEJM199309303291401.
. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837–853.
. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97(17):1695–1701. doi: 10.1161/01.cir.97.17.1695.
. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35(8):771–776. doi: 10.1007/BF00429099.
. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27(3):567–574. doi: 10.1016/0735-1097(95)00522-6.
. Kelley DE, Mokan M, Simoneau JA, et al. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest 1993;92(1):91–98. doi: 10.1172/JCI116603.
. Steinberg HO, Paradisi G, Hook G, et al. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000;49(7):1231–1238. doi: 10.2337/diabetes.49.7.1231.
. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997;100(5):1230–1239. doi: 10.1172/JCI119636.
. Ghosh A, Gao L, Thakur A, et al. Role of free fatty acids in endothelial dysfunction. J Biomed Sci 2017;24(1):50. doi: 10.1186/s12929-017-0357-5.
. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14(3):173–194. doi: 10.2337/diacare.14.3.173.
. Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007;104(31):12587–12594. doi: 10.1073/pnas.0705408104.
. Muniyappa R, Montagnani M, Koh KK, et al. Cardiovascular actions of insulin. Endocr Rev 2007;28(5):463–491. doi: 10.1210/er.2007-0006.
. Vincent MA, Clerk LH, Lindner JR, et al. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 2004;53(6):1418–1423. doi: 10.2337/diabetes.53.6.1418.
. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 2013;14(1):5–12. doi: 10.1007/s11154-012-9229-1.
. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259(5091):87–91. doi: 10.1126/science.7678183.
. Dandona P, Aljada A, Chaudhuri A, et al. Endothelial dysfunction, inflammation and diabetes. Rev Endocr Metab Disord 2004;5(3):189–197. doi: 10.1023/B:REMD.0000032407.88070.0a.
. Tsalamandris S, Antonopoulos AS, Oikonomou E, et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol 2019;14(1):50–59. doi: 10.15420/ecr.2018.33.1.
. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007;380(1/2):24–30. doi: 10.1016/j.cca.2007.01.026.
. Grattagliano I, Palmieri VO, Portincasa P, et al. Oxidative stress
-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2008;19(8):491–504. doi: 10.1016/j.jnutbio.2007.06.011.
. Roberts CK, Sindhu KK. Oxidative stress
and metabolic syndrome. Life Sci 2009;84(21/22):705–712. doi: 10.1016/j.lfs.2009.02.026.
. Poulsen HE, Specht E, Broedbaek K, et al. RNA modifications by oxidation: a novel disease mechanism. Free Radic Biol Med 2012;52(8):1353–1361. doi: 10.1016/j.freeradbiomed.2012.01.009.
. Van Campenhout A, Van Campenhout C, Lagrou AR, et al. Impact of diabetes mellitus on the relationships between iron-, inflammatory- and oxidative stress
status. Diabetes Metab Res Rev 2006;22(6):444–454. doi: 10.1002/dmrr.635.
. Chang CM, Hsieh CJ, Huang JC, et al. Acute and chronic fluctuations in blood glucose levels can increase oxidative stress
in type 2 diabetes mellitus. Acta Diabetol 2012;49(Suppl 1):S171–S177. doi: 10.1007/s00592-012-0398-x.
. Johansen JS, Harris AK, Rychly DJ, et al. Oxidative stress
and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005;4:5. doi: 10.1186/1475-2840-4-5.
. Mehta JL, Rasouli N, Sinha AK, et al. Oxidative stress
in diabetes: a mechanistic overview of its effects on atherogenesis and myocardial dysfunction. Int J Biochem Cell Biol 2006;38(5/6):794–803. doi: 10.1016/j.biocel.2005.12.008.
. Sedeek M, Montezano AC, Hebert RL, et al. Oxidative stress
, Nox isoforms and complications of diabetes – potential targets for novel therapies. J Cardiovasc Transl Res 2012;5(4):509–518. doi: 10.1007/s12265-012-9387-2.
. Preedy VR. Diabetes: Oxidative Stress
and Dietary Antioxidants. Amsterdam, The Netherland: Elsevier Science; 2013.
. Rösen P, Nawroth PP, King G, et al. The role of oxidative stress
in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001;17(3):189–212. doi: 10.1002/dmrr.196.
. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414(6865):813–820. doi: 10.1038/414813a.
. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404(6779):787–790. doi: 10.1038/35008121.
. Paneni F, Costantino S, Cosentino F. Role of oxidative stress
in endothelial insulin resistance. World J Diabetes 2015;6(2):326–332. doi: 10.4239/wjd.v6.i2.326.
. Ralevic V, Milla PJ, Burnstock G. Effects of chronic vitamin E deficiency on vascular function – a study of sympathetic nerves, smooth muscle and endothelium of the mesenteric arterial bed of the rat. Br J Pharmacol 1995;116(7):2983–2988. doi: 10.1111/j.1476-5381.1995.tb15953.x.
. Davidge ST, Ojimba J, McLaughlin MK. Vascular function in the vitamin E-deprived rat: an interaction between nitric oxide and superoxide anions. Hypertension 1998;31(3):830–835. doi: 10.1161/01.hyp.31.3.830.
. Hogikyan RV, Galecki AT, Pitt B, et al. Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity. J Clin Endocrinol Metab 1998;83(6):1946–1952. doi: 10.1210/jcem.83.6.4907.
. Mäkimattila S, Liu ML, Vakkilainen J, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 1999;22(6):973–981. doi: 10.2337/diacare.22.6.973.
. Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97(1):22–28. doi: 10.1172/JCI118394.
. Timimi FK, Ting HH, Haley EA, et al. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998;31(3):552–557. doi: 10.1016/s0735-1097(97)00536-6.
. Laight DW, Carrier MJ, Anggård EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 2000;47(3):457–464. doi: 10.1016/s0008-6363(00)00054-7.
. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87(1):245–313. doi: 10.1152/physrev.00044.2005.
. Hakami NY, Ranjan AK, Hardikar AA, et al. Role of NADPH oxidase-4 in human endothelial progenitor cells. Front Physiol 2017;8:150. doi: 10.3389/fphys.2017.00150.
. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C – dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000;49(11):1939–1945. doi: 10.2337/diabetes.49.11.1939.
. Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances apoptosis related to oxidative stress
in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52(11):2795–2804. doi: 10.2337/diabetes.52.11.2795.
. Ding H, Aljofan M, Triggle CR. Oxidative stress
and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. J Cell Physiol 2007;212(3):682–689. doi: 10.1002/jcp.21063.
. DeVallance E, Li Y, Jurczak MJ, et al. The role of NADPH oxidases in the etiology of obesity and metabolic syndrome: contribution of individual isoforms and cell biology. Antioxid Redox Signal 2019;31(10):687–709. doi: 10.1089/ars.2018.7674.
. Fortuño A, San José G, Moreno MU, et al. Phagocytic NADPH oxidase overactivity underlies oxidative stress
in metabolic syndrome. Diabetes 2006;55(1):209–215. doi: 10.2337/diabetes.55.01.06.db05-0751.
. Maloney E, Sweet IR, Hockenbery DM, et al. Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol 2009;29(9):1370–1375. doi: 10.1161/ATVBAHA.109.188813.
. Chinen I, Shimabukuro M, Yamakawa K, et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007;148(1):160–165. doi: 10.1210/en.2006-1132.
. Sukumar P, Viswambharan H, Imrie H, et al. Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction. Diabetes 2013;62(6):2130–2134. doi: 10.2337/db12-1294.
. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34(3):267–273. doi: 10.1038/ng1180.
. Widlansky ME, Gutterman DD. Regulation of endothelial function by mitochondrial reactive oxygen species. Antioxid Redox Signal 2011;15(6):1517–1530. doi: 10.1089/ars.2010.3642.
. Riva A, Tandler B, Loffredo F, et al. Structural differences in two biochemically defined populations of cardiac mitochondria. Am J Physiol Heart Circ Physiol 2005;289(2):H868–H872. doi: 10.1152/ajpheart.00866.2004.
. Morino K, Petersen KF, Dufour S, et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 2005;115(12):3587–3593. doi: 10.1172/JCI25151.
. Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350(7):664–671. doi: 10.1056/NEJMoa031314.
. Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A 2006;103(8):2653–2658. doi: 10.1073/pnas.0511154103.
. Basta G, Lazzerini G, Del Turco S, et al. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol 2005;25(7):1401–1407. doi: 10.1161/01.ATV.0000167522.48370.5e.
. Srinivasan S, Yeh M, Danziger EC, et al. Glucose regulates monocyte adhesion through endothelial production of interleukin-8. Circ Res 2003;92(4):371–377. doi: 10.1161/01.RES.0000061714.74668.5C.
. Lee KU, Lee IK, Han J, et al. Effects of recombinant adenovirus-mediated uncoupling protein 2 overexpression on endothelial function and apoptosis. Circ Res 2005;96(11):1200–1207. doi: 10.1161/01.RES.0000170075.73039.5b.
. Wang Q, Zhang M, Torres G, et al. Metformin suppresses diabetes-accelerated atherosclerosis via the inhibition of Drp1-mediated mitochondrial fission. Diabetes 2017;66(1):193–205. doi: 10.2337/db16-0915.
. Lee SH, Du J, Stitham J, et al. Inducing mitophagy in diabetic platelets protects against severe oxidative stress
. EMBO Mol Med 2016;8(7):779–795. doi: 10.15252/emmm.201506046.
. Zhan M, Usman IM, Sun L, et al. Disruption of renal tubular mitochondrial quality control by Myo-inositol oxygenase in diabetic kidney disease. J Am Soc Nephrol 2015;26(6):1304–1321. doi: 10.1681/ASN.2014050457.
. Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress
: cross-talk and redox signalling. Biochem J 2012;441(2):523–540. doi: 10.1042/BJ20111451.
. Zhu W, Yuan Y, Liao G, et al. Mesenchymal stem cells ameliorate hyperglycemia-induced endothelial injury through modulation of mitophagy. Cell Death Dis 2018;9(8):837. doi: 10.1038/s41419-018-0861-x.
. Lazzarino G, Listorti I, Bilotta G, et al. Water- and fat-soluble antioxidants in human seminal plasma and serum of fertile males. Antioxidants (Basel) 2019;8(4):96. doi: 10.3390/antiox8040096.
. Vendemiale G, Grattagliano I, Altomare E. An update on the role of free radicals and antioxidant defense in human disease. Int J Clin Lab Res 1999;29(2):49–55. doi: 10.1007/s005990050063.
. Patel M, Day BJ. Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol Sci 1999;20(9):359–364. doi: 10.1016/s0165-6147(99)01336-x.
. Palace VP, Khaper N, Qin Q, et al. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Free Radic Biol Med 1999;26(5-6):746–761. doi: 10.1016/s0891-5849(98)00266-4.
. Kendall MJ, Nuttall SL, Martin U. Antioxidant therapy – a new therapeutic option for reducing mortality from coronary artery disease. J Clin Pharm Ther 1998;23(5):323–325. doi: 10.1046/j.1365-2710.1998.00179.x.
. Gaziano JM. Antioxidant vitamins and cardiovascular disease. Proc Assoc Am Physicians 1999;111(1):2–9. doi: 10.1046/j.1525-1381.1999.09229.x.
. Beckman JA, Goldfine AB, Gordon MB, et al. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001;103(12):1618–1623. doi: 10.1161/01.cir.103.12.1618.
. Mendoza SA, Fang J, Gutterman DD, et al. TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress. Am J Physiol Heart Circ Physiol 2010;298(2):H466–H476. doi: 10.1152/ajpheart.00854.2009.
. Mertens S, Noll T, Spahr R, et al. Energetic response of coronary endothelial cells to hypoxia. Am J Physiol 1990;258(3 Pt 2):H689–H694. doi: 10.1152/ajpheart.1990.258.3.H689.
. Migliaccio E, Giorgio M, Mele S, et al. The p66shc adaptor protein controls oxidative stress
response and life span in mammals. Nature 1999;402(6759):309–313. doi: 10.1038/46311.
. Banfi C, Brioschi M, Barbieri SS, et al. Mitochondrial reactive oxygen species: a common pathway for PAR1- and PAR2-mediated tissue factor induction in human endothelial cells. J Thromb Haemost 2009;7(1):206–216. doi: 10.1111/j.1538-7836.2008.03204.x.
. Graham D, Huynh NN, Hamilton CA, et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 2009;54(2):322–328. doi: 10.1161/HYPERTENSIONAHA.109.130351.
. Laight DW, Carrier MJ, Anggård EE. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev 1999;15(4):274–282. doi: 10.1002/(sici)1520-7560(199907/08)15.
. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002;109(6):817–826. doi: 10.1172/JCI14442.
. Xu J, Xie Z, Reece R, et al. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol 2006;26(12):2688–2695. doi: 10.1161/01.ATV.0000249394.94588.82.
. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003;111(8):1201–1209. doi: 10.1172/JCI14172.
. Zou MH, Shi C, Cohen RA. High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 2002;51(1):198–203. doi: 10.2337/diabetes.51.1.198.
. Woods A, Cheung PC, Smith FC, et al. Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. J Biol Chem 1996;271(17):10282–10290. doi: 10.1074/jbc.271.17.10282.
. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003;13(22):2004–2008. doi: 10.1016/j.cub.2003.10.031.
. Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003;2(4):28. doi: 10.1186/1475-4924-2-28.
. Hong SP, Leiper FC, Woods A, et al. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc Natl Acad Sci U S A 2003;100(15):8839–8843. doi: 10.1073/pnas.1533136100.
. Kishi K, Yuasa T, Minami A, et al. AMP-Activated protein kinase is activated by the stimulations of G(q)-coupled receptors. Biochem Biophys Res Commun 2000;276(1):16–22. doi: 10.1006/bbrc.2000.3417.
. Hawley SA, Pan DA, Mustard KJ, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005;2(1):9–19. doi: 10.1016/j.cmet.2005.05.009.
. Hurley RL, Anderson KA, Franzone JM, et al. The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 2005;280(32):29060–29066. doi: 10.1074/jbc.M503824200.
. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8(11):1288–1295. doi: 10.1038/nm788.
. Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 2002;99(25):16309–16313. doi: 10.1073/pnas.222657499.
. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415(6869):339–343. doi: 10.1038/415339a.
. Atkinson LL, Fischer MA, Lopaschuk GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem 2002;277(33):29424–29430. doi: 10.1074/jbc.M203813200.
. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277(28):25226–25232. doi: 10.1074/jbc.M202489200.
. Zou MH, Kirkpatrick SS, Davis BJ, et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004;279(42):43940–43951. doi: 10.1074/jbc.M404421200.
. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108(8):1167–1174. doi: 10.1172/JCI13505.
. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51(7):2074–2081. doi: 10.2337/diabetes.51.7.2074.
. Zhang F, Dey D, Bränström R, et al. BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner. Am J Physiol Cell Physiol 2009;296(2):C346–354. doi: 10.1152/ajpcell.00444.2008.
. Zou MH, Hou XY, Shi CM, et al. Modulation by peroxynitrite of Akt- and AMP-activated kinase-dependent Ser1179 phosphorylation of endothelial nitric oxide synthase. J Biol Chem 2002;277(36):32552–32557. doi: 10.1074/jbc.M204512200.
. Choi SL, Kim SJ, Lee KT, et al. The regulation of AMP-activated protein kinase by H(2)O(2). Biochem Biophys Res Commun 2001;287(1):92–97. doi: 10.1006/bbrc.2001.5544.
. Viollet B, Athea Y, Mounier R, et al. AMPK: Lessons from transgenic and knockout animals. Front Biosci (Landmark Ed) 2009;14:19–44. doi: 10.2741/3229.
. Yang Q, Xu J, Ma Q, et al. PRKAA1/AMPKα1-driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis. Nat Commun 2018;9(1):4667. doi: 10.1038/s41467-018-07132-x.
. Fisslthaler B, Fleming I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res 2009;105(2):114–127. doi: 10.1161/CIRCRESAHA.109.201590.
. Davis BJ, Xie Z, Viollet B, et al. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006;55(2):496–505. doi: 10.2337/diabetes.55.02.06.db05-1064.
. Schulz E, Anter E, Zou MH, et al. Estradiol-mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation 2005;111(25):3473–3480. doi: 10.1161/CIRCULATIONAHA.105.546812.
. Chen Z, Peng IC, Sun W, et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 2009;104(4):496–505. doi: 10.1161/CIRCRESAHA.108.187567.
. Zippel N, Loot AE, Stingl H, et al. Endothelial AMP-activated kinase α1 phosphorylates eNOS on Thr495 and decreases endothelial NO formation. Int J Mol Sci 2018;19(9):2753. doi: 10.3390/ijms19092753.
. Wang S, Zhang M, Liang B, et al. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res 2010;106(6):1117–1128. doi: 10.1161/CIRCRESAHA.109.212530.
. Coughlan KA, Valentine RJ, Ruderman NB, et al. AMPK activation: a therapeutic target for type 2 diabetes. Diabetes Metab Syndr Obes 2014;7:241–253. doi: 10.2147/DMSO.S43731.
. Ruderman NB, Carling D, Prentki M, et al. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013;123(7):2764–2772. doi: 10.1172/JCI67227.
. Livingstone R, Boyle JG, Petrie JR. A new perspective on metformin therapy in type 1 diabetes. Diabetologia 2017;60(9):1594–1600. doi: 10.1007/s00125-017-4364-6.
. Ma X, Zhang J, Wu Z, et al. Chicoric acid attenuates hyperglycemia-induced endothelial dysfunction through AMPK-dependent inhibition of oxidative/nitrative stresses. J Recept Signal Transduct Res 2020;1–15. doi: 10.1080/10799893.2020.1817076.
. Ceolotto G, Gallo A, Papparella I, et al. Rosiglitazone reduces glucose-induced oxidative stress
mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler Thromb Vasc Biol 2007;27(12):2627–2633. doi: 10.1161/ATVBAHA.107.155762.
. Song P, Zou MH. Regulation of NAD(P)H oxidases by AMPK in cardiovascular systems. Free Radic Biol Med 2012;52(9):1607–1619. doi: 10.1016/j.freeradbiomed.2012.01.025.
. Alba G, El Bekay R, Alvarez-Maqueda M, et al. Stimulators of AMP-activated protein kinase inhibit the respiratory burst in human neutrophils. FEBS Lett 2004;573(1-3):219–225. doi: 10.1016/j.febslet.2004.07.077.
. Bonnefont-Rousselot D, Raji B, Walrand S, et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress
. Metabolism 2003;52(5):586–589. doi: 10.1053/meta.2003.50093.
. Gargiulo P, Caccese D, Pignatelli P, et al. Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes Metab Res Rev 2002;18(2):156–159. doi: 10.1002/dmrr.282.
. Cho YE, Basu A, Dai A, et al. Coronary endothelial dysfunction and mitochondrial reactive oxygen species in type 2 diabetic mice. Am J Physiol Cell Physiol 2013;305(10):C1033–C1040. doi: 10.1152/ajpcell.00234.2013.
. Matsumoto S, Gotoh N, Hishinuma S, et al. The role of hypertriglyceridemia in the development of atherosclerosis and endothelial dysfunction. Nutrients 2014;6(3):1236–1250. doi: 10.3390/nu6031236.
. Zmijewski JW, Moellering DR, Le Goffe C, et al. Oxidized LDL induces mitochondrially associated reactive oxygen/nitrogen species formation in endothelial cells. Am J Physiol Heart Circ Physiol 2005;289(2):H852–H861. doi: 10.1152/ajpheart.00015.2005.
. Li J, Wang Y, Wang Y, et al. Pharmacological activation of AMPK prevents Drp1-mediated mitochondrial fission and alleviates endoplasmic reticulum stress-associated endothelial dysfunction. J Mol Cell Cardiol 2015;86:62–74. doi: 10.1016/j.yjmcc.2015.07.010.
. Wang Q, Wu S, Zhu H, et al. Deletion of PRKAA triggers mitochondrial fission by inhibiting the autophagy-dependent degradation of DNM1L. Autophagy 2017;13(2):404–422. doi: 10.1080/15548627.2016.1263776.
. Bhatt MP, Lim YC, Kim YM, et al. C-peptide activates AMPKα and prevents ROS-mediated mitochondrial fission and endothelial apoptosis in diabetes. Diabetes 2013;62(11):3851–3862. doi: 10.2337/db13-0039.
. Xie Z, Zhang J, Wu J, et al. Upregulation of mitochondrial uncoupling protein-2 by the AMP-activated protein kinase in endothelial cells attenuates oxidative stress
in diabetes. Diabetes 2008;57(12):3222–3230. doi: 10.2337/db08-0610.
. Kukidome D, Nishikawa T, Sonoda K, et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006;55(1):120–127.
. Liangpunsakul S, Wou SE, Zeng Y, et al. Effect of ethanol on hydrogen peroxide-induced AMPK phosphorylation. Am J Physiol Gastrointest Liver Physiol 2008;295(6):G1173–G1181. doi: 10.1152/ajpgi.90349.2008.
. Han Y, Wang Q, Song P, et al. Redox regulation of the AMP-activated protein kinase. PLoS One 2010;5(11):e15420. doi: 10.1371/journal.pone.0015420.
. Hinchy EC, Gruszczyk AV, Willows R, et al. Mitochondria-derived ROS activate AMP-activated protein kinase (AMPK) indirectly. J Biol Chem 2018;293(44):17208–17217. doi: 10.1074/jbc.RA118.002579.
. Rabinovitch RC, Samborska B, Faubert B, et al. AMPK maintains cellular metabolic homeostasis through regulation of mitochondrial reactive oxygen species. Cell Rep 2017;21(1):1–9. doi: 10.1016/j.celrep.2017.09.026.
. Wu S, Zou MH. AMPK, mitochondrial function, and cardiovascular disease. Int J Mol Sci 2020;21(14):4987. doi: 10.3390/ijms21144987.
. Avery SV. Molecular targets of oxidative stress
. Biochem J 2011;434(2):201–210. doi: 10.1042/BJ20101695.
. Cecarini V, Gee J, Fioretti E, et al. Protein oxidation and cellular homeostasis: emphasis on metabolism. Biochim Biophys Acta 2007;1773(2):93–104. doi: 10.1016/j.bbamcr.2006.08.039.
. Zmijewski JW, Banerjee S, Bae H, et al. Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase. J Biol Chem 2010;285(43):33154–33164. doi: 10.1074/jbc.M110.143685.
. Pieper GM, Gross GJ. Oxygen free radicals abolish endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol 1988;255(4 Pt 2):H825–H833. doi: 10.1152/ajpheart.1988.255.4.H825.
. Langenstroer P, Pieper GM. Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals. Am J Physiol 1992;263(1 Pt 2):H257–H265. doi: 10.1152/ajpheart.1992.263.1.H257.
. Diederich D, Skopec J, Diederich A, et al. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol 1994;266(3 Pt 2):H1153–H1161. doi: 10.1152/ajpheart.1994.266.3.H1153.
. Hattori Y, Kawasaki H, Abe K, et al. Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol 1991;261(4 Pt 2):H1086–H1094. doi: 10.1152/ajpheart.1991.261.4.H1086.
. Keegan A, Walbank H, Cotter MA, et al. Chronic vitamin E treatment prevents defective endothelium-dependent relaxation in diabetic rat aorta. Diabetologia 1995;38(12):1475–1478. doi: 10.1007/BF00400609.
. Rösen P, Ballhausen T, Bloch W, et al. Endothelial relaxation is disturbed by oxidative stress
in the diabetic rat heart: influence of tocopherol as antioxidant. Diabetologia 1995;38(10):1157–1168. doi: 10.1007/BF00422364.
. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320(6061):454–456. doi: 10.1038/320454a0.
. Darley-Usmar V, White R. Disruption of vascular signalling by the reaction of nitric oxide with superoxide: implications for cardiovascular disease. Exp Physiol 1997;82(2):305–316. doi: 10.1113/expphysiol.1997.sp004026.
. Choi HC, Song P, Xie Z, et al. Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. J Biol Chem 2008;283(29):20186–20197. doi: 10.1074/jbc.M803020200.
. An Z, Wang H, Song P, et al. Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress. J Biol Chem 2007;282(37):26793–26801. doi: 10.1074/jbc.M703701200.
. Xie Z, Dong Y, Zhang M, et al. Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells. J Biol Chem 2006;281(10):6366–6375. doi: 10.1074/jbc.M511178200.
. Irrcher I, Ljubicic V, Hood DA. Interactions between ROS and AMP kinase activity in the regulation of PGC-1alpha transcription in skeletal muscle cells. Am J Physiol Cell Physiol 2009;296(1):C116–C123. doi: 10.1152/ajpcell.00267.2007.
. Park IJ, Hwang JT, Kim YM, et al. Differential modulation of AMPK signaling pathways by low or high levels of exogenous reactive oxygen species in colon cancer cells. Ann N Y Acad Sci 2006;1091:102–109. doi: 10.1196/annals.1378.059.
. Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 2004;3(4):340–351. doi: 10.1038/nrd1344.
. Xu XJ, Gauthier MS, Hess DT, et al. Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress
, and depot-specific changes in gene expression in adipose tissue. J Lipid Res 2012;53(4):792–801. doi: 10.1194/jlr.P022905.
. Bandyopadhyay GK, Yu JG, Ofrecio J, et al. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 2006;55(8):2277–2285. doi: 10.2337/db06-0062.
. Xie Z, Lau K, Eby B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 2011;60(6):1770–1778. doi: 10.2337/db10-0351.
. Liang X, Zhang T, Shi L, et al. Ampelopsin protects endothelial cells from hyperglycemia-induced oxidative damage by inducing autophagy via the AMPK signaling pathway. Biofactors 2015;41(6):463–475. doi: 10.1002/biof.1248.
. García-Prieto CF, Hernández-Nuño F, Rio DD, et al. High-fat diet induces endothelial dysfunction through a down-regulation of the endothelial AMPK-PI3K-Akt-eNOS pathway. Mol Nutr Food Res 2015;59(3):520–532. doi: 10.1002/mnfr.201400539.
. Wagner TM, Mullally JE, Fitzpatrick FA. Reactive lipid species from cyclooxygenase-2 inactivate tumor suppressor LKB1/STK11: cyclopentenone prostaglandins and 4-hydroxy-2-nonenal covalently modify and inhibit the AMP-kinase kinase that modulates cellular energy homeostasis and protein translation. J Biol Chem 2006;281(5):2598–2604. doi: 10.1074/jbc.M509723200.
. Dolinsky VW, Chan AY, Robillard Frayne I, et al. Resveratrol prevents the prohypertrophic effects of oxidative stress
on LKB1. Circulation 2009;119(12):1643–1652. doi: 10.1161/CIRCULATIONAHA.108.787440.
. Shao D, Oka S, Liu T, et al. A redox-dependent mechanism for regulation of AMPK activation by Thioredoxin1 during energy starvation. Cell Metab 2014;19(2):232–245. doi: 10.1016/j.cmet.2013.12.013.
. Ren Y, Shen HM. Critical role of AMPK in redox regulation under glucose starvation. Redox Biol 2019;25:101154. doi: 10.1016/j.redox.2019.101154.